First-Trimester Use of Paroxetine and Congenital Heart Defects: A Population-Based Case-Control Study

Eurocat Northern Netherlands, Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Birth Defects Research Part A Clinical and Molecular Teratology (Impact Factor: 2.09). 11/2009; 88(2):94-100. DOI: 10.1002/bdra.20641
Source: PubMed


There is a need for case-control studies of the effect of paroxetine on the occurrence of specific heart defects.
We performed a case-control study with data from a population-based birth defects registry in the Netherlands. All the children born between 1997 and 2006 were selected. Cases were defined as fetuses and children with isolated heart defects, and the controls were fetuses and children with a genetic disorder with no heart defect. We excluded children for whom there was no information on maternal medication use and deceased children and fetuses who were not examined postmortem. First-trimester exposure to paroxetine was compared between cases and controls by calculating adjusted odds ratios (AOR).
We included 678 cases with isolated heart defects and 615 controls. The first trimester exposure rate was 1.5% for cases and 1.0% for controls. After excluding mothers who used paroxetine outside the first trimester, or who had used another SSRI, we found no significantly increased risk for heart defects overall (10 exposed cases; AOR, 1.5; 95% confidence interval [CI], 0.5-4.0), but we did find a significantly increased risk for atrium septum defects (three exposed cases; AOR, 5.7; 95% CI, 1.4-23.7).
Our results suggest that the use of paroxetine in early pregnancy is associated with an increased risk of atrium septum defects. The results stress the importance of studying possible teratogenic effects of a drug, preferably in regard to well-specified malformations.

Download full-text


Available from: Wilhelmina S Kerstjens-Frederikse,
  • Source
    • "Studies with larger cohorts have shown an association between first trimester antidepressant exposure and congenital heart defects, particularly septal defects.93,94,98,111–117 Although these results have not been replicated in several other studies,51,87,90,97,100,118–124 a small increase in the risk of any cardiac malformation or septal heart defect has been consistently reported across meta-analyses (Table 3), particularly for paroxetine,105–107 and in one case fluoxetine.108 "
    [Show abstract] [Hide abstract]
    ABSTRACT: In pregnant women with major depression, the overarching goal of treatment is to achieve or maintain maternal euthymia, thus limiting both maternal and fetal exposure to the harmful effects of untreated or incompletely treated depression. However, the absence of uniformly effective therapies with guaranteed obstetric and fetal safety makes the treatment of major depression during pregnancy among the most formidable of clinical challenges. Clinicians and patients are still faced with conflicting data and expert opinion regarding the reproductive safety of antidepressants in pregnancy, as well as large gaps in our understanding of the effectiveness of most antidepressants and nonpharmacological alternatives for treating antenatal depression. In this paper, we provide a clinically focused review of the available information on potential maternal and fetal risks of untreated maternal depression during pregnancy, the effectiveness of interventions for maternal depression during pregnancy, and potential obstetric, fetal, and neonatal risks associated with antenatal antidepressant use.
    Drug, Healthcare and Patient Safety 09/2014; 6:109-29. DOI:10.2147/DHPS.S43308
  • Source
    • "Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly used medications in pregnancy, with prescription frequency estimates in pregnant women ranging from 0.7 to 1.4 % in Nordic countries (Jimenez- Solem et al. 2013; Kieler et al. 2012) and 5–13 % in the United States (Andrade et al. 2008; Cooper et al. 2007; Ramos et al. 2008). There is accumulating evidence that mothers treated with SSRIs during pregnancy may experience increased rates of adverse reproductive outcomes (Bakker et al. 2010; Lund et al. 2009). In addition, recent studies have suggested a possible link between prenatal antidepressant exposure and neurodevelopmental outcomes including altered speech perception (Weikum et al. 2012) and motor, social–emotional and adaptive behavior (Hanley et al. 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark's health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child's risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers.
    Journal of Autism and Developmental Disorders 05/2014; 44(10). DOI:10.1007/s10803-014-2128-4 · 3.06 Impact Factor
  • Source
    • "A possible association between cardiovascular anomalies and first-trimester exposure to fluoxetine has been suggested by Diav-Citrin et al. (2008). Gestational exposure to paroxetine is associated with major congenital malformations and major cardiac malformations for only first trimester exposure above 25 mg/day; there is an increased prevalence of septal heart defects among children whose mothers were prescribed with SSRIs in early pregnancy (Bakker et al., 2010), although the teratogenic potential of paroxetine that has been reported in some studies remains unproven (Gentile and Bellantuono, 2009; Tuccori et al., 2010). The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI (Pedersen et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The objective of our study was to analyze the efficacy and the safety of SSRIs during pregnancy. Methods: A group of 30 pregnant women affected by Major Depressive Disorder by SCID I interview (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision criteria) and treated with selective serotonin reuptake inhibitor (SSRI) were included in the study. They were matched to a comparison group of 26 pregnant women. Results: There were no statistically significant differences in any of the pregnancy outcomes of interest between the treated women and comparison group. There was no statistically significant association in newborns of women treated with an SSRI and the control group in the first and fifth minute Apgar score, and no newborns were admitted to neonatal Intensive Care Units. Conclusions: No definitive association between use of SSRIs during pregnancy and an increased risk of birth defects or other adverse outcomes could be found.
    Human Psychopharmacology Clinical and Experimental 11/2012; 28(1). DOI:10.1002/hup.2276 · 2.19 Impact Factor
Show more